Britannia Life Sciences Inc (BLAB) AI Stock Analysis

• Market Cap: C$9.74M
• Dividend Yield: N/A
• Average Volume (3M): 55.21K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.84
• Revenue Growth: -3.93%
• EPS Growth: -575.24%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 44
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 162,254,330
• 10 Day Avg. Volume: 19,827
• 30 Day Avg. Volume: 55,212
• PEG Ratio: -0.02
• Price to Book (P/B): 2.19
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 17.62
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 42 Neutral
• Price Target: ―

Britannia Life Sciences displays significant financial challenges with high leverage and inconsistent revenue, negatively impacting its stock score. The technical analysis indicates weak momentum, and valuation metrics are poor. However, the recent strategic sale of a subsidiary provides a slight positive outlook, contributing to a modest score improvement.

Britannia Life Sciences Inc Business Overview & Revenue Model

Company Description

Britannia Life Sciences Inc (BLAB) is a company engaged in providing a comprehensive suite of services to the cosmetic, nutraceutical, and consumer goods sectors. The company specializes in product formulation, quality assurance, regulatory compliance, and consumer testing. By leveraging its expertise, Britannia Life Sciences supports businesses in bringing innovative products to market efficiently and in compliance with industry standards.

How the Company Makes Money

Britannia Life Sciences Inc generates its revenue through a variety of service-based offerings tailored to the needs of the cosmetic, nutraceutical, and consumer goods industries. The company earns income by providing product formulation services, which involve creating and testing new product formulations for clients. Additionally, it offers quality assurance and regulatory compliance services, ensuring that products meet necessary legal and safety standards before they reach the market. Consumer testing services also contribute to revenue by providing insights into product performance and consumer preferences. Partnerships with industry players and a focus on delivering comprehensive solutions further enhance Britannia Life Sciences' revenue streams.

Britannia Life Sciences Inc Financial Statement Overview

Summary

Britannia Life Sciences Inc. faces significant financial challenges. The income statement reflects operational inefficiencies with negative EBIT and EBITDA, and inconsistent revenue growth. The balance sheet highlights high leverage with low equity, posing financial risks. Cash flow shows some positive operating cash flow but remains volatile due to underlying profitability issues.

Income Statement

The company's income statement reveals significant challenges. The TTM data shows a decrease in revenue and a negative EBIT and EBITDA, indicating operational inefficiencies. Net income is also negative, reflecting poor profitability. The gross profit margin is relatively stable but not enough to offset the high operational costs. Revenue growth over the past year has been inconsistent, with a decline from the previous year, indicating market or operational challenges.

Balance Sheet

The balance sheet highlights financial instability with a high debt-to-equity ratio and low equity. The company's equity is minimal compared to its liabilities, posing financial risk. Return on equity is negative due to sustained net losses. The equity ratio is low, indicating potential solvency issues. Overall, the balance sheet suggests the company is highly leveraged, with significant financial risks.

Cash Flow

The cash flow statement shows some positive aspects, such as positive operating cash flow in the TTM period, which indicates some ability to generate cash from operations. However, the free cash flow growth rate is volatile, and the free cash flow to net income ratio is unstable due to negative net income. The company has managed to reduce capital expenditures, which helps improve free cash flow, but cash flow challenges remain due to underlying profitability issues.

Breakdown
TTM	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Income Statement		Total Revenue
7.19M	7.57M	6.40M	7.30M	1.42M	974.27K
	Gross Profit
4.09M	4.85M	4.64M	5.26M	1.17M	285.38K
	EBIT
-5.06M	173.00K	177.74K	379.57K	114.83K	-5.20M
	EBITDA
-5.09M	-1.90M	6.95M	-10.77M	-1.62M	-5.35M
	Net Income Common Stockholders
-7.98M	-4.77M	5.08M	-15.46M	-157.16K	-7.13M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
990.37K	1.32M	2.60M	1.63M	828.32K	2.18M
	Total Assets
22.17M	22.26M	23.55M	21.09M	21.45M	3.16M
	Total Debt
7.11M	7.29M	8.41M	5.19M	10.55M	9.34M
	Net Debt
6.12M	5.96M	5.81M	3.56M	9.72M	7.16M
	Total Liabilities
16.33M	15.59M	12.49M	15.61M	18.79M	13.24M
	Stockholders Equity
1.18M	2.44M	7.02M	1.35M	-202.32K	-10.08M
Cash Flow		Free Cash Flow
654.30K	1.75M	874.41K	2.71M	-543.49K	-5.25M
	Operating Cash Flow
1.11M	2.09M	1.22M	2.80M	-586.58K	-5.18M
	Investing Cash Flow
-460.06K	-1.44M	-3.32M	653.95K	-4.91M	-68.38K
	Financing Cash Flow
-1.46M	-1.97M	2.95M	-2.58M	6.20M	3.55M

Britannia Life Sciences Inc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.06
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BLAB, the sentiment is Negative. The current price of 0.06 is below the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.07, and below the 200-day MA of 0.06, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 41.42 is Neutral, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:BLAB.

Britannia Life Sciences Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.38B	3.40	-45.06%	3.28%	16.75%	-0.02%
KNE	45 Neutral	C$9.12M	―	-813.02%	―	―	―
BLAB	42 Neutral	C$9.74M	―	-175.45%	―	-3.93%	-575.24%
BIOV	29 Underperform	$10.20M	―		―	―	48.63%
BETR	21 Underperform	C$14.55M	―	26.73%	―	―	-62.39%

Britannia Life Sciences Inc Corporate Events

Britannia Life Sciences Strengthens Financial Position with Strategic Sale

Britannia Life Sciences Inc. has completed the sale of its UK operating subsidiary, Advanced Development and Safety Laboratories Inc., resulting in net proceeds of approximately $13 million. The company is prioritizing strategic capital allocation to optimize shareholder returns and support sustainable growth. Britannia is also focusing on its investment in Britannia Mining Solutions, recognizing its potential to drive value and align with the company’s strategic goals.